Minimal information available on the clinical use of lanadelumab during breastfeeding indicated no infant harm. Because lanadelumab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] If lanadelumab is required by the mother, it is not a reason to discontinue breastfeeding. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3]
目前尚无关于哺乳期使用拉那度单抗的临床信息。由于拉那度单抗是一种分子量约为146,000道尔顿的大蛋白质分子，乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中部分被破坏，婴儿的吸收可能极少。[2]产后至少等待2周再恢复治疗可能会将药物转移至婴儿的情况降至最低。[3]在获得更多数据之前，哺乳期使用拉那度单抗时应谨慎，尤其是在哺育新生儿或早产儿期间。
